Spots Global Cancer Trial Database for pancreatic
Every month we try and update this database with for pancreatic cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors | NCT01628913 | Pancreatic Neur... | BEZ235 Everolimus | 18 Years - | Novartis | |
| Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma | NCT01233375 | Metastatic Panc... | CO-1.01 | 18 Years - | Clovis Oncology, Inc. | |
| Ultrasound-assisted Treatment of Inoperable Pancreatic Cancer | NCT01674556 | Pancreatic Aden... | Gemzar | - | Haukeland University Hospital | |
| A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors | NCT02605083 | Cancer | eFT508 | 18 Years - | Effector Therapeutics | |
| Depression, Cytokines and Pancreatic Cancer | NCT00582699 | Pancreatic Canc... | assessment inte... | 40 Years - | Memorial Sloan Kettering Cancer Center | |
| A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies | NCT04503265 | Advanced Malign... Breast Cancer Ovarian Cancer Homologous Reco... Prostate Cancer Pancreatic Canc... | AMXI-5001:Dose ... AMXI-5001:Dose ... | 18 Years - | AtlasMedx, Incorporated | |
| Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC | NCT03665441 | Pancreatic Aden... | eryaspase Gemcitabine plu... Irinotecan plus... | 18 Years - | ERYtech Pharma | |
| Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization | NCT00434109 | Neuroendocrine ... Islet Cell Tumo... | Sunitinib malat... Hepatic Artery ... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer | NCT01025570 | Pancreatic Canc... | Gemcitabine, Bo... | 18 Years - | University of California, San Francisco | |
| LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer | NCT02705196 | Pancreatic Canc... | delolimogene mu... gemcitabine nab-paclitaxel atezolizumab | 18 Years - | Lokon Pharma AB | |
| High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | NCT03697239 | Metastatic Panc... Pancreatic Canc... Pancreas Cancer Pancreatic Aden... Pancreatic Duct... Pancreatic Meta... | Ascorbic Acid Paclitaxel prot... Cisplatin Gemcitabine | 18 Years - | University of California, San Diego | |
| EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options | NCT03602885 | Metastatic Panc... Unresectable Pa... Metastatic Colo... | Usual chemother... Chemotherapy ed... | 21 Years - | Dana-Farber Cancer Institute | |
| FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer | NCT01688336 | Pancreatic Canc... | FOLFIRINOX | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Comparing Endoscopic Based Stent Strategy Versus Bypass Surgery in Non-resectable Periampullary Cancer | NCT00487851 | Pancreatic Neop... Biliary Tract N... Duodenal Neopla... | surgery endoscopic stra... | - | Karolinska Institutet | |
| Immunochemoradiotherapy in Patients With Pancreatic Cancer | NCT01342224 | Locally Advance... | tadalafil and v... | 18 Years - | Providence Health & Services | |
| Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) | NCT01253161 | Neuroendocrine ... Carcinoid Tumor... | Pasireotide Lon... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer | NCT00401570 | Pancreatic Canc... | Volociximab Gemcitabine | 18 Years - | AbbVie | |
| Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients. | NCT04652206 | Metastatic Panc... Locally Advance... Inoperable Dise... Localized Pancr... | SCO-101 Gemcitabine Nab paclitaxel | 18 Years - | Scandion Oncology A/S | |
| Clinical Trial Evaluating Low Dose G-FLIP Plus Mitomycin C for Stage IV Pancreatic Cancer | NCT06233877 | Pancreatic Canc... | G-GLIP plus Mit... | 18 Years - | Hirschfeld Oncology | |
| A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors | NCT02549937 | Tumors | surufatinib | 18 Years - | Hutchmed | |
| A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer | NCT00336700 | Pancreatic Canc... | Gemcitabine Erlotinib | 18 Years - | University of Pittsburgh | |
| QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel | NCT02559674 | Advanced Pancre... | Gemcitabine Nab-paclitaxel ALT-803 | 18 Years - | Altor BioScience | |
| Study of Minnelide™ in Patients With Advanced GI Tumors | NCT01927965 | Advanced Gastro... | Minnelide™ 001 | 18 Years - | Minneamrita Therapeutics LLC | |
| A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies | NCT04678648 | Advanced Malign... RAS Mutation Lung Cancer Colon Cancer Glioblastoma Pancreatic Canc... | RSC-1255 Dose E... RSC-1255 Dose E... | 18 Years - | RasCal Therapeutics, Inc. | |
| A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma | NCT00998322 | Metastatic Panc... | REOLYSIN Gemcitabine | 18 Years - | Oncolytics Biotech | |
| Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy | NCT00363051 | Islet Cell Carc... Neuroendocrine ... Neuroendocrine ... Pancreatic Neop... | Everolimus 10 m... Octreotide Depo... | 18 Years - | Novartis | |
| TAS-102 (Lonsurf) in Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Post First Line Chemotherapy (UF-STO-PANC-003) | NCT02921737 | Pancreatic Canc... | TAS-102 | 18 Years - 90 Years | University of Florida | |
| Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) | NCT01253161 | Neuroendocrine ... Carcinoid Tumor... | Pasireotide Lon... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | NCT03697239 | Metastatic Panc... Pancreatic Canc... Pancreas Cancer Pancreatic Aden... Pancreatic Duct... Pancreatic Meta... | Ascorbic Acid Paclitaxel prot... Cisplatin Gemcitabine | 18 Years - | University of California, San Diego | |
| Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | NCT04902872 | Solid Tumor, Ad... Epithelial Ovar... Small Cell Lung... Breast Cancer Colorectal Canc... Pancreas Cancer Appendix Cancer Non-small Cell ... Gastric Cancer Esophagus Cance... Urothelial Carc... Sarcoma | CBX-12 | 18 Years - | Cybrexa Therapeutics | |
| Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract | NCT01770405 | Pancreatic Cyst Pancreatic Neop... Pancreatic Aden... Pancreatic Canc... Pancreatic Isle... Lymph Node Mass Lymphadenopathy GIST | Endoscopic ultr... | 18 Years - | Mauna Kea Technologies | |
| Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer | NCT01830322 | Metastatic Panc... | CPI-613 Gemcitabine Any non-gemcita... | 18 Years - 85 Years | Cornerstone Pharmaceuticals | |
| EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options | NCT03602885 | Metastatic Panc... Unresectable Pa... Metastatic Colo... | Usual chemother... Chemotherapy ed... | 21 Years - | Dana-Farber Cancer Institute | |
| Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS) | NCT01096732 | Pancreatic Duct... | GDC-0449 | 18 Years - | Cambridge University Hospitals NHS Foundation Trust | |
| Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors | NCT01628913 | Pancreatic Neur... | BEZ235 Everolimus | 18 Years - | Novartis | |
| Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer | NCT03096093 | Cancer Neoplasms | ACIT-1 | 18 Years - | Cancer Vaccines Limited | |
| A Study to Assess PV-10 Chemoablation of Cancer of the Liver | NCT00986661 | Cancer Metastat... Hepatocellular ... Metastatic Mela... Metastatic Ocul... Metastatic Uvea... Metastatic Lung... Metastatic Colo... Metastatic Colo... Metastatic Brea... Metastatic Panc... | PV-10 (10% rose... | 18 Years - | Provectus Pharmaceuticals | |
| Multi-Modality Therapy for Untreated Patients With Resectable or Marginally Resectable Pancreatic Cancer | NCT01760694 | Pancreatic Canc... | Multi-Modality;... | 18 Years - | Southwestern Regional Medical Center | |
| Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer | NCT02790944 | Pancreatic Duct... | Multi-gene Next... | 18 Years - 89 Years | Ambry Genetics | |
| A Phase I Study of ECO-4601 in Patients With Advanced Cancer | NCT00338026 | Tumors Glioma Colorectal Canc... Lung Cancer Breast Cancer Ovarian Cancer Pancreatic Canc... Prostate Cancer | ECO-4601 | 18 Years - | Thallion Pharmaceuticals | |
| LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer | NCT02705196 | Pancreatic Canc... | delolimogene mu... gemcitabine nab-paclitaxel atezolizumab | 18 Years - | Lokon Pharma AB | |
| High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | NCT03908333 | Metastatic Panc... Pancreatic Canc... Pancreas Cancer Pancreatic Aden... Pancreatic Duct... Pancreatic Meta... | Ascorbic Acid Paclitaxel prot... Cisplatin Gemcitabine | 18 Years - | Medical College of Wisconsin | |
| A Study of the Effect of Gemcitabine With Fish Oil in Patients With Advanced Pancreatic Cancer | NCT01019382 | Pancreatic Neop... | Lipidem fish oi... | 18 Years - | University Hospitals, Leicester | |
| Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma | NCT02620423 | Pancreatic Aden... | REOLYSIN® Chemotherapy Gemcitabine Irinotecan Leucovorin 5-fluorouracil Pembrolizumab | 18 Years - | Oncolytics Biotech | |
| A Pilot Study of BXCL701 in Patients With Pancreatic Cancer | NCT04123574 | Cancer of Pancr... Cancer of the P... Neoplasms, Panc... Pancreas Cancer Pancreatic Canc... | Talabostat Mesy... | 18 Years - 75 Years | BioXcel Therapeutics Inc | |
| Diagnostic Accuracy of Circulating Tumor Cells (CTCs) and Onco-exosome Quantification in the Diagnosis of Pancreatic Cancer - PANC-CTC | NCT03032913 | Pancreatic Duct... | Blood samples Portal vein blo... | 18 Years - | University Hospital, Bordeaux | |
| A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors | NCT02605083 | Cancer | eFT508 | 18 Years - | Effector Therapeutics | |
| High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | NCT03908333 | Metastatic Panc... Pancreatic Canc... Pancreas Cancer Pancreatic Aden... Pancreatic Duct... Pancreatic Meta... | Ascorbic Acid Paclitaxel prot... Cisplatin Gemcitabine | 18 Years - | Medical College of Wisconsin | |
| Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive | NCT01262040 | Endometrial Can... Fallopian Tube ... Ovarian Cancer Peritoneal Canc... Gastrointestina... Pancreatic Carc... Lung Cancer Esophageal Carc... | Narrow Band Ima... | 19 Years - | Memorial Sloan Kettering Cancer Center | |
| Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer | NCT00426127 | Pancreatic Canc... | Docetaxel Liposomal Doxor... Enoxaparin | 18 Years - | University of Iowa | |
| Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies | NCT01401907 | Non-small Cell ... Small Cell Lung... Mesothelioma Esophageal Canc... Gastric Cancer Liver Cancer Pancreatic Canc... | early palliativ... | 18 Years - | Massachusetts General Hospital | |
| Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET | NCT01374451 | Islet Cell Tumo... | Everolimus Pasireotide LAR | 18 Years - | Novartis | |
| Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats | NCT01078662 | Ovarian Breast Prostate Pancreatic Advanced Tumour... | olaparib | 18 Years - 130 Years | AstraZeneca | |
| Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer | NCT00557492 | Pancreatic Canc... | Avastin (bevaci... Gemzar (Gemcita... external beam r... | 18 Years - 80 Years | University of Pittsburgh | |
| Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients | NCT05065801 | Metastatic Panc... | GABRINOX FOLFIRINOX | 18 Years - 75 Years | Institut du Cancer de Montpellier - Val d'Aurelle | |
| High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | NCT03697239 | Metastatic Panc... Pancreatic Canc... Pancreas Cancer Pancreatic Aden... Pancreatic Duct... Pancreatic Meta... | Ascorbic Acid Paclitaxel prot... Cisplatin Gemcitabine | 18 Years - | University of California, San Diego | |
| Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma | NCT02620423 | Pancreatic Aden... | REOLYSIN® Chemotherapy Gemcitabine Irinotecan Leucovorin 5-fluorouracil Pembrolizumab | 18 Years - | Oncolytics Biotech | |
| A Phase II Study of Neoadjuvant FOLFIRINOX | NCT02178709 | Resectable Panc... | FOLFIRINOX | 18 Years - | Indiana University | |
| Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic Cancer | NCT01908478 | Pancreatic Canc... | Veliparib Gemcitabine Intensity modul... | 18 Years - | Cedars-Sinai Medical Center | |
| Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer | NCT03009058 | Metastatic Canc... | IMM-101 Gemcitabine Nabpaclitaxel Capecitabine Folinic Acid Fluorouracil Irinotecan Oxaliplatin cetuximab Anti-PD1 Ipilimumab Cyclophosphamid... | 18 Years - | Immodulon Therapeutics Ltd | |
| Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer | NCT03009058 | Metastatic Canc... | IMM-101 Gemcitabine Nabpaclitaxel Capecitabine Folinic Acid Fluorouracil Irinotecan Oxaliplatin cetuximab Anti-PD1 Ipilimumab Cyclophosphamid... | 18 Years - | Immodulon Therapeutics Ltd | |
| High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | NCT03797443 | Metastatic Panc... | Ascorbic Acid nab paclitaxel Cisplatin Gemcitabine | 18 Years - | Piedmont Cancer Institute | |
| Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients | NCT05065801 | Metastatic Panc... | GABRINOX FOLFIRINOX | 18 Years - 75 Years | Institut du Cancer de Montpellier - Val d'Aurelle | |
| Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas | NCT00837031 | Metastatic Panc... | Lenalidomide Gemcitabine | 18 Years - | SCRI Development Innovations, LLC | |
| Acelarin First Line Randomised Pancreatic Study | NCT03610100 | Pancreatic Acin... Pancreatic Neop... | Acelarin Gemcitabine | 18 Years - | The Clatterbridge Cancer Centre NHS Foundation Trust | |
| Trimodal Prehabilitation in Pancreatic Cancer Patients Urdergoing Neoadjuvant Treatment | NCT05722223 | Pancreatic Neop... | Trimodal prehab... | 18 Years - | Puerta de Hierro University Hospital | |
| A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer | NCT01025570 | Pancreatic Canc... | Gemcitabine, Bo... | 18 Years - | University of California, San Francisco | |
| Multi-Modality Therapy for Untreated Patients With Resectable or Marginally Resectable Pancreatic Cancer | NCT01760694 | Pancreatic Canc... | Multi-Modality;... | 18 Years - | Southwestern Regional Medical Center | |
| 7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients | NCT00841035 | Pancreatic Canc... | erlotinib | 19 Years - 80 Years | University of Alabama at Birmingham | |
| A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma | NCT00998322 | Metastatic Panc... | REOLYSIN Gemcitabine | 18 Years - | Oncolytics Biotech | |
| A Phase I/II, Multi-Center, Open-Label, Dose-Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients With Advanced Pancreatic Carcinoma | NCT00411762 | Pancreatic Canc... | Capecitabine PHY906 | 18 Years - | Yale University | |
| Dose Escalation Study of CyberKnife® SBRT Boost for Patients With Unresectable Locally Advanced Pancreatic Cancer | NCT01872377 | Pancreatic Carc... | CyberKnife® Ste... | 19 Years - 80 Years | Ottawa Hospital Research Institute | |
| A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers | NCT00660699 | Cholangiocarcin... Gallbladder Can... Pancreatic Canc... Ampullary Cance... | Gemcitabine Docetaxel Radiation | 18 Years - | Washington University School of Medicine | |
| A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors | NCT02743637 | Advanced Malign... Advanced Solid ... Neoplasm Metastasis | SDX-7320 | 21 Years - 85 Years | SynDevRx, Inc. | |
| Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma | NCT00177242 | Cancer | Gefitinib | 18 Years - | University of Pittsburgh | |
| Distal Pancreatectomy, Minimally Invasive or Open, for Malignancy (DIPLOMA) | NCT04483726 | Pancreatic Duct... | minimally invas... open distal pan... | 18 Years - | University Hospital, Montpellier | |
| A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer | NCT02908451 | Gastric Cancer Colorectal Canc... Pancreatic Canc... Biliary Cancer | AbGn-107 | 18 Years - | AbGenomics B.V Taiwan Branch | |
| Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma | NCT00177242 | Cancer | Gefitinib | 18 Years - | University of Pittsburgh | |
| Diagnostic Accuracy of Circulating Tumor Cells (CTCs) and Onco-exosome Quantification in the Diagnosis of Pancreatic Cancer - PANC-CTC | NCT03032913 | Pancreatic Duct... | Blood samples Portal vein blo... | 18 Years - | University Hospital, Bordeaux | |
| Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer | NCT01453153 | Stage IV Pancre... | Gemcitabine PEGPH20 Placebo | 18 Years - | Halozyme Therapeutics |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
